Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 180 Show results per page	View Search Criteria \| Help With Results


1.		Phase II/III Autologous Stem Cell Reinfusion Following ARA-C/BCNU for CML in Blast Crisis

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				no age specified								NCI-D82-018-544 DFCI-80051, DFCI-CML


2.		Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				CSTI571H2201 NCT00290771


3.		Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				CSTI571H2202 NCT00292149

Last Modified: 2/13/2003


4.		Phase III Randomized Study of Consolidation and Maintenance Therapy With Hydroxyurea and Interferon alfa Versus Cytarabine, Idarubicin, and Interferon alfa After Allogeneic Bone Marrow Transplantation in Patients With Chronic Phase Chronic Myelogenous Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Any age				Other				GER-CML-3 EU-95042, NCT00002771

Last Modified: 5/8/2007 First Published: 11/1/1996


5.		Phase III Randomized Study of Interferon alfa With or Without Cytarabine Versus Autologous Peripheral Blood Stem Cell Transplantation Followed by Interferon alfa With or Without Cytarabine in Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase (Summary Last Modified 03/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				15 to 65				NCI				MRC-LEUK-CML-2000 ECOG-E7995, MRC-LEUK-CML-IV, MRC-LEUK-CML-IVa, EU-96029, NCT00002868, E7995

Last Modified: 2/28/2008 First Published: 11/1/1996


6.		Phase III Randomized Study of Low- vs High-Dose Interferon alfa for Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				adult								MRC-LEUK-CML-V EU-96028, NCT00002869

Last Modified: 12/1/1998 First Published: 12/1/1997


7.		Phase III Comparison Study of Subcutaneous Interferon Alfa-2b with or without Cytarabine After Cytoreduction with Hydroxyurea in Chronic Phase Chronic Myeloid Leukemia (Summary Last Modified 12/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Over 18				Other				CMLNSG-99 NCI-V97-1349

Last Modified: 6/12/2007 First Published: 3/1/2000


8.		Phase III Randomized Study of Homoharringtonine Versus Hydroxyurea in Patients With Interferon alfa Refractory Chronic Myelogenous Leukemia (Summary Last Modified 06/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				16 and over				NCI				CLB-19807 SWOG-C19807, NCT00004933, C19807

Last Modified: 12/10/2007 First Published: 6/1/2000


9.		Phase III Randomized Study of Intensive Versus Nonintensive Chemotherapy in Older Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				60 and over				Other				LRF-AML14 EU-20016, NCT00005823, ISRCTN62207270

Last Modified: 3/23/2007


10.		Phase III LSA2-L2 Chemotherapy with CTX/VCR/MTX/DNM/PRED and Radiotherapy and Surgery for Childhood non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				under 18				NCI				POG-7615 MDAR-18, MDAR-190

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute